Published in Mol Ther on June 01, 2002
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther (2011) 1.87
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood (2012) 1.64
Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61
Retroviral integrations in gene therapy trials. Mol Ther (2012) 1.34
Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07
Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity. Front Med (2011) 1.05
Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation. Clin Cancer Res (2008) 1.03
T-cell therapies for HIV. Immunotherapy (2013) 0.99
Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther (2010) 0.98
Stem cell-based anti-HIV gene therapy. Virology (2011) 0.94
HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies. J Virol (2016) 0.89
Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes. Mol Med (2011) 0.88
Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology (2013) 0.88
Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs. Curr Opin HIV AIDS (2011) 0.86
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells (2014) 0.85
Evaluation of engraftment and immunological tolerance after reduced intensity conditioning in a rhesus hematopoietic stem cell gene therapy model. Gene Ther (2013) 0.85
Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Semin Oncol (2016) 0.84
Eradication of human immunodeficiency virus from brain reservoirs. J Neurovirol (2014) 0.84
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. J Virol (2015) 0.84
HIV cure research: a formidable challenge. J Virus Erad (2015) 0.83
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Mol Ther (2013) 0.82
CCR5 as a natural and modulated target for inhibition of HIV. Viruses (2013) 0.82
Gene therapy strategies to exploit TRIM derived restriction factors against HIV-1. Viruses (2014) 0.81
Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81
Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells. Mol Ther (2017) 0.81
Combining Cell and Gene Therapy in an Effort to Eradicate HIV. AIDS Patient Care STDS (2016) 0.80
Lentivector Knockdown of CCR5 in Hematopoietic Stem and Progenitor Cells Confers Functional and Persistent HIV-1 Resistance in Humanized Mice. J Virol (2015) 0.80
Gene therapy strategies for HIV/AIDS: preclinical modeling in humanized mice. Viruses (2013) 0.80
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
Gene therapy targeting HIV entry. Viruses (2014) 0.79
Mathematical modeling of oncogenesis control in mature T-cell populations. Front Immunol (2013) 0.78
Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251. Retrovirology (2004) 0.78
A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol (2014) 0.78
T-Cell Therapy: Options for Infectious Diseases. Clin Infect Dis (2015) 0.78
Leveraging Cancer Therapeutics for the HIV Cure Agenda: Current Status and Future Directions. Drugs (2015) 0.77
Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection. Curr Opin HIV AIDS (2015) 0.77
Ectopic expression of anti-HIV-1 shRNAs protects CD8(+) T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation. Biochem Biophys Res Commun (2015) 0.77
Therapeutic T cell engineering. Nature (2017) 0.77
Chimeric antigen receptor-modified T cells strike back. Int Immunol (2016) 0.76
Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015. Hum Gene Ther (2015) 0.76
Can engineered "designer" T cells outsmart chronic hepatitis B? Hepat Res Treat (2010) 0.76
Is gene therapy a good therapeutic approach for HIV-positive patients? Genet Vaccines Ther (2007) 0.76
Toward synthetic biology with engineered T cells: a long journey just begun. Hum Gene Ther (2014) 0.75
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer (2017) 0.75
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. Cancer Gene Ther (2017) 0.75
A curative regimen would decrease HIV prevalence but not HIV incidence unless targeted to an ART-naïve population. Sci Rep (2016) 0.75
T-cell therapies for HIV: Preclinical successes and current clinical strategies. Cytotherapy (2016) 0.75
Engineering HIV-Specific Immunity with Chimeric Antigen Receptors. AIDS Patient Care STDS (2016) 0.75
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Mol Ther (2017) 0.75
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med (2017) 0.75
Cell-based gene therapy against HIV. Gene Ther (2015) 0.75
Novel immunological strategies for HIV-1 eradication. J Virus Erad (2015) 0.75
Chimeric antigen receptor engineered stem cells: a novel HIV therapy. Immunotherapy (2017) 0.75
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 12.58
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature (2006) 9.20
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
A human memory T cell subset with stem cell-like properties. Nat Med (2011) 7.47
Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet (2008) 7.30
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
The CD28 signaling pathway regulates glucose metabolism. Immunity (2002) 6.65
Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature (2008) 6.61
In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature (2005) 6.60
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature (2005) 5.54
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature (2010) 5.43
Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A (2009) 5.36
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10
Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell (2012) 4.67
A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell (2007) 4.59
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med (2005) 4.17
Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest (2005) 4.10
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother (2006) 4.02
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Therapeutic targeting of a stem cell niche. Nat Biotechnol (2007) 3.88
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell (2008) 3.84
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Oocyte generation in adult mammalian ovaries by putative germ cells in bone marrow and peripheral blood. Cell (2005) 3.77
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
The hematopoietic stem cell in its place. Nat Immunol (2006) 3.70
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell (2008) 3.62
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature (2010) 3.55
Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol (2002) 3.43
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
BioHealthBase: informatics support in the elucidation of influenza virus host pathogen interactions and virulence. Nucleic Acids Res (2007) 3.28
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses (2012) 3.04
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. Mol Ther (2007) 2.99
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Xist RNA is a potent suppressor of hematologic cancer in mice. Cell (2013) 2.93
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
Limiting factors in murine hematopoietic stem cell assays. Cell Stem Cell (2007) 2.89
CARs on track in the clinic. Mol Ther (2011) 2.86
The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood (2009) 2.85
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med (2007) 2.79
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med (2015) 2.77
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells (2009) 2.76
Evaluation of an HIV nucleic acid testing program with automated Internet and voicemail systems to deliver results. Ann Intern Med (2010) 2.69
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. Blood (2002) 2.66
In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18INK4C. Nat Cell Biol (2004) 2.65
Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol (2007) 2.65
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat Med (2008) 2.64
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood (2007) 2.64
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood (2004) 2.63
The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol (2007) 2.59
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc (2007) 2.59
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J Infect Dis (2003) 2.54